Puma Biotechnology | PBYI - Attività Correnti





Attività Correnti Cambiamento Data
Agios Pharmaceuticals USD 752.1M 34.43M 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amgen USD 34.36B 598M 2026-09
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Daiichi Sankyo JPY 2.38T 150.33B 2026-09
Exelixis USD 1.32B 70.8M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Glaxosmithkline GBP 17.9B 134M 2026-09
Incyte USD 5.52B 505.2M 2026-09
MacroGenics USD 321.69M 139.16M 2026-06
Moderna USD 7.34B 1.53B 2026-09
Novartis USD 28.75B 1.4B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
PTC Therapeutics USD 2.54B 79.58M 2026-09
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.27B 49.06M 2026-09
Takeda JPY 3T 153.11B 2026-09
TG Therapeutics USD 1.15B 58.72M 2026-06
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09